WO1999036030A3 - Pharmaceutical composition and method for treating di-hydroxytestosterone dependent conditions - Google Patents
Pharmaceutical composition and method for treating di-hydroxytestosterone dependent conditions Download PDFInfo
- Publication number
- WO1999036030A3 WO1999036030A3 PCT/US1999/001207 US9901207W WO9936030A3 WO 1999036030 A3 WO1999036030 A3 WO 1999036030A3 US 9901207 W US9901207 W US 9901207W WO 9936030 A3 WO9936030 A3 WO 9936030A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- treating
- androgenic
- dependent conditions
- binds
- dosage form
- Prior art date
Links
- 230000001419 dependent effect Effects 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- AKHONHCNYRUTLT-NXBFSHDWSA-N (8R,9S,10R,13S,14S,17S)-15,15,17-trihydroxy-10,13-dimethyl-2,6,7,8,9,11,12,14,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-one Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4(O)O)O)[C@@H]4[C@@H]3CCC2=C1 AKHONHCNYRUTLT-NXBFSHDWSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 230000001548 androgenic effect Effects 0.000 abstract 3
- 229940113178 5 Alpha reductase inhibitor Drugs 0.000 abstract 2
- 239000002677 5-alpha reductase inhibitor Substances 0.000 abstract 2
- 239000006186 oral dosage form Substances 0.000 abstract 2
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 abstract 2
- 229960002256 spironolactone Drugs 0.000 abstract 2
- 201000004384 Alopecia Diseases 0.000 abstract 1
- 201000002996 androgenic alopecia Diseases 0.000 abstract 1
- 230000002280 anti-androgenic effect Effects 0.000 abstract 1
- 239000011248 coating agent Substances 0.000 abstract 1
- 238000000576 coating method Methods 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000013268 sustained release Methods 0.000 abstract 1
- 239000012730 sustained-release form Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A pharmaceutical composition for treating DHT dependent conditions including androgenic alopecia is disclosed. An oral dosage form according to the invention includes a therapeutically effective amount of a 5α-Reductase inhibitor and another active compound which binds with androgenic receptors. In a preferred form, the bio-available concentration of the compound which binds with androgenic receptors is limited or controlled to avoid appreciable anti-androgenic side effects, for example, by providing a controlled (timed or sustained release) coating on that active compound. Spironolactone is a particularly preferred compound which binds with androgenic receptors. A preferred dosage form has the ratio of the 5α-Reductase inhibitor to spironolactone in the range of 1:5 to 1:2500. A method for creating an oral dosage form for treating DHT dependent conditions is also disclosed.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU24619/99A AU2461999A (en) | 1998-01-16 | 1999-01-19 | Pharmaceutical composition and method for treating di-hydroxytestosterone dependent conditions |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US796498A | 1998-01-16 | 1998-01-16 | |
| US09/007,964 | 1998-01-16 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1999036030A2 WO1999036030A2 (en) | 1999-07-22 |
| WO1999036030A3 true WO1999036030A3 (en) | 1999-09-23 |
Family
ID=21729079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1999/001207 WO1999036030A2 (en) | 1998-01-16 | 1999-01-19 | Pharmaceutical composition and method for treating di-hydroxytestosterone dependent conditions |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU2461999A (en) |
| WO (1) | WO1999036030A2 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7790706B2 (en) | 2002-06-14 | 2010-09-07 | The University Of Edinburgh | Treatment of inflammation with 5α reduced metabolites |
| GB0213745D0 (en) * | 2002-06-14 | 2002-07-24 | Univ Edinburgh | Enzyme |
| DE10303509A1 (en) * | 2002-08-23 | 2004-03-04 | Koc, Felix, Dr. | Hair growth promoting composition contains finasteride for oral administration in combination with biotin or for external administration |
| RU2316328C1 (en) * | 2006-05-30 | 2008-02-10 | Государственное образовательное учреждение дополнительного профессионального образования Санкт-Петербургская медицинская академия последипломного образования Федерального агентства по здравоохранению и социальному развитию | Method for correction of partial age androgen deficiency (padam) and preparative formulation of testosterone or its pharmacologically acceptable derivatives for its realization |
| US20120245205A1 (en) | 2009-07-29 | 2012-09-27 | Delong Mitchell A | Compositions and methods for inhibiting hair growth |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995017168A1 (en) * | 1993-12-21 | 1995-06-29 | Applied Analytical Industries, Inc. | Method for preparing low dose pharmaceutical products |
-
1999
- 1999-01-19 WO PCT/US1999/001207 patent/WO1999036030A2/en not_active Application Discontinuation
- 1999-01-19 AU AU24619/99A patent/AU2461999A/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995017168A1 (en) * | 1993-12-21 | 1995-06-29 | Applied Analytical Industries, Inc. | Method for preparing low dose pharmaceutical products |
Non-Patent Citations (3)
| Title |
|---|
| ERENUS M., ET AL.: "COMPARISON OF FINASTERIDE VERSUS SPIRONOLACTONE IN THE TREATMENT OFIDIOPATHIC HIRSUTISM.", FERTILITY AND STERILITY., ELSEVIER SCIENCE INC, NEW YORK, NY, USA, vol. 68., no. 06., 1 December 1997 (1997-12-01), USA, pages 1000 - 1003., XP002920808, ISSN: 0015-0282, DOI: 10.1016/S0015-0282(97)00371-3 * |
| KNOCHENHAUER E. S., AZZIZ R.: "ADVANCES IN THE DIAGNOSIS AND TREATMENT OF THE HIRSUTE PATIENT.", CURRENT OPINION IN OBSTETRICS AND GYNECOLOGY., RAPID SCIENCE PUBLISHERS., US, vol. 07., no. 05., 1 October 1995 (1995-10-01), US, pages 344 - 350., XP000618511, ISSN: 1040-872X * |
| SHAW J. C.: "ANTIANDROGEN THERAPY IN DERMATOLOGY.", INTERNATIONAL JOURNAL OF DERMATOLOGY, WILEY-BLACKWELL PUBLISHING LTD., UK, vol. 35., no. 11., 1 November 1996 (1996-11-01), UK, pages 770 - 778., XP002920809, ISSN: 0011-9059, DOI: 10.1111/j.1365-4362.1996.tb02970.x * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO1999036030A2 (en) | 1999-07-22 |
| AU2461999A (en) | 1999-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI973828L (en) | Compounds and compositions for delivering active ingredients | |
| AU5699399A (en) | Pyridyl-bridgehead derivatives and their analogues, pharmaceutical compositions and their use as inhibitors of nicotinic cholinergic receptors | |
| BG106030A (en) | Pharmaceutical composition | |
| MXPA03011494A (en) | Composition and method for improving plant growth. | |
| HUP9900457A3 (en) | Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents | |
| WO1998051294A3 (en) | Method and composition for treating cancers | |
| MY133564A (en) | Compositions and methods for treating osteoporosis and lowering cholesterol | |
| CA2366702A1 (en) | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents | |
| HK1039328A1 (en) | Pyrazolopyrimidinone derivatives for the treatment of impotence | |
| MY122159A (en) | A multiparticulate modified release composition | |
| AP1745A (en) | Pharmaceutical compositions of amlodipine and atorvastatin. | |
| NO982006L (en) | Therapeutic preparation for transdermal delivery of active substances through the skin | |
| AU6202299A (en) | Compositions for the treatment and prevention of neurological and pathopsychological diseases | |
| WO2001030802A3 (en) | Therapeutic treatments comprising administration of certain steroids for blood cell deficiencies | |
| WO2002060392A3 (en) | Use of gal3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | |
| WO1999063976A3 (en) | Liver-selective glucocorticoid antagonist for treating diabetes | |
| DK0724444T3 (en) | Method of treating androgenic alopecia with inhibitors of 5-alpha reductase | |
| HUP0003982A3 (en) | The use of inhibitors of the renin-angiotensin system for producing pharmaceutical compositions using for the treatment of hypoxia or impaired metabolic function | |
| IL139861A0 (en) | 17β-AMINO-AND HYDROXYLAMINO -11 β-ARYLSTEROID DERIVATIVES, METHODS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | |
| WO1999036030A3 (en) | Pharmaceutical composition and method for treating di-hydroxytestosterone dependent conditions | |
| CA2320878A1 (en) | Morphine sulphate microgranules, method for making same and pharmaceutical preparations | |
| IL142598A0 (en) | Preparations for topical application of substances having antiandrogenic effect | |
| CA2214601A1 (en) | Mercapto and seleno derivatives as inhibitors of nitric oxide synthase | |
| HK1024164A1 (en) | Use of composition and a cosmetic method for reducing or preventing stinging | |
| HUP0101898A3 (en) | Meiosis regulating steroid derivatives and use thereof for producing pharmaceutical compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| 122 | Ep: pct application non-entry in european phase | ||
| WA | Withdrawal of international application |